Prescription of opioid analgesics and related harms in Australia

There has been growing concern among Australian medical professionals about the increase in prescribing of opioid analgesic preparations (particularly morphine and oxycodone) over the past decade. Australia’s consumption of opioid analgesics is ranked 10th internationally; North America ranks first. Per capita consumption of oxycodone and morphine preparations in Australia is relatively high (ranked third and fifth respectively, internationally); Canada ranks first for oxycodone and Australia first for morphine.1 Consumption levels in Australia are still well below the top-ranking countries. Previous research in Australia has documented increases in the number of prescriptions for morphine in the late 1990s2,3 and, more recently, increases in consumption of oxycodone.4

Morphine and oxycodone have legitimate and important treatment indications in the management of pain. Access to effective pain management is an important human right, and pain, both acute and chronic, imposes a major public health burden internationally.5 Morphine (and codeine) are listed by the World Health Organization as drugs of choice for treating chronic and severe cancer pain.6 Opioid analgesics are also widely used for pain not related to cancer.7 However, there are as yet no overarching international guidelines about prescribing these drugs in broader pain management presentations.8

One of the chief concerns about the increased availability of opioid medications is the potential for a concomitant increase in non-medical use (in this article, this term refers to use of substances without prescription) and diversion (buying, selling or passing on drugs, outside of prescribed use). Non-medical use and diversion are complex behaviours, and may occur among different groups of consumers, including patients with chronic non-malignant pain, patients with cancer pain and illicit drug users.7,9

Abstract

Objective: To document trends in: (i) prescribing of morphine and oxycodone; (ii) hospital separations for overdose; (iii) presentations for treatment of problems associated with these drugs; and (iv) oxycodone-related mortality data in Australia.

Design and setting: Cross-sectional study analysing prescriptions for morphine and oxycodone based on figures adjusted using Australian Bureau of Statistics estimated resident population and prospectively collected data from: (i) the National Hospital Morbidity Database on hospital separations primarily attributed to poisoning with opioids other than heroin (“other opioids”); (ii) the Alcohol and Other Drug Treatment National Minimum Data Set for treatment episodes where morphine or oxycodone were the primary or other drugs of concern; and (iii) the National Coronial Information System on deaths where oxycodone was the underlying cause of death or a contributory factor.

Main outcome measures: Population-adjusted numbers of (i) prescriptions for morphine and oxycodone by 10-year age group, (ii) hospital separations for “other opioid” poisoning, and (iii) treatment episodes related to morphine or oxycodone; and (iv) number of oxycodone-related deaths.

Results: Prescriptions for morphine declined, while those for oxycodone increased. Prescriptions for both were highest among older Australians. Hospital separations for “other opioid” poisoning doubled between the financial years 2005–06 and 2006–07. Treatment episodes for morphine remained stable, while those for oxycodone increased. There were 465 oxycodone-related deaths recorded during 2001–2009.

Conclusions: Oxycodone prescriptions in Australia have increased, particularly among older Australians. The increase may, in part, reflect appropriate prescribing for pain among an ageing population. However we are unable to differentiate non-medical use from appropriate prescribing from this data. In comparison to heroin, the morbidity and mortality associated with oxycodone is relatively low in Australia. There is a continued need for comprehensive training of general practitioners in assessing patients with chronic non-malignant pain and prescribing of opioids for these patients, to minimise the potential for harms associated with use of these medications.

Methods

Prescription data

Morphine and oxycodone prescription data (2002–2008) were obtained from the Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee.

Numbers of morphine prescriptions for oral preparations, by year, were collected for: 10mg, 20mg and 30mg immediate-release tablets;
5mg, 10mg, 15mg, 30mg, 60mg, 100mg and 200mg controlled-release tablets; 30mg, 60mg, 90mg and 120mg controlled-release capsules; and 10mg, 20mg, 50mg and 100mg sustained-release capsules. Numbers of oxycodone prescriptions for oral preparations, by year, were collected for: 5mg tablets; 10mg, 20mg, 40mg and 80mg controlled-release tablets; and 5mg, 10mg and 20mg capsules. Results are presented per 1000 population, by 10-year age group.

Hospital separations
We present data from the National Hospital Morbidity Database (NHMD) for the financial years 1999–00 to 2007–08. These are coded according to the International classification of diseases and related health problems, 10th revision, clinical modification (ICD-10-CM). We present hospital separations where the principal diagnosis was “other opioid” poisoning; this poisoning code includes morphine, oxycodone and codeine.

Treatment presentations
We present data from the Alcohol and Other Drug Treatment Services National Minimum Data Set (AODTS-NMDS) for the financial years 2002–03 to 2007–08. Data represent the number of treatment episodes where morphine or oxycodone was the primary drug, or other drug, of concern, and relate to closed treatment episodes (which means some episodes may be excluded if the patient did not finish treatment within the given time frame).

Deaths
It is difficult to distinguish between deaths from heroin and from morphine because of the way that heroin is metabolised. It is likely that many deaths recorded as morphine-related deaths may be heroin-related. Accordingly, we examined only oxycodone-related deaths. The National Coronial Information System (NCIS) was searched for deaths where oxycodone toxicity or overdose was recorded as a direct or contributory cause of death (2001–2009), and where oxycodone was found at fatal levels in the blood. Only closed cases, where the final cause of death had been determined by the coroner, were included. The NCIS contains coronial files from all states and territories in Australia. Searches were conducted using the category “pharmaceutical substance for human use”, and either leaving the descriptor field for these substances blank or specifying the subcategory as “analgesic, antipyretic, antirheumatic”, and further specifying “oxycodone”. Free text searches were also conducted on findings documents, which yielded some extra cases. Only deaths where oxycodone was mentioned were included in analyses.

We present numbers of oxycodone deaths, and adjusted numbers of oxycodone deaths per million defined daily doses of oral oxycodone preparations prescribed in that year.

Data analysis
Analyses were conducted using PASW Statistics version 18.0 (SPSS Inc, Chicago, Ill, USA). Numbers of prescriptions per 1000 population were calculated using the Australian Bureau of Statistics (ABS) estimates of the population as at 30 June for each corresponding year. Trends in changes over time in prescriptions and dose formulations were analysed using ordinary least squares linear regression; all trends (except where noted) were strongly linear and, in all cases, findings concurred with non-parametric (Spearman) correlation techniques. Differences between injecting drug users (IDUs) and non-IDU decedents were analysed using t test, odds ratio and χ² analyses.

Ethics approval
This study was approved by the Human Research Ethics Committees of the University of New South Wales, and the Victorian Department of Justice.

Results

Prescription trends in Australia
Morphine prescriptions declined from 38.3 to 30.7 per 1000 population between 2002–03 and 2007–08, representing a decrease of about 20%. Box 1A shows trends in morphine prescriptions by 10-year age group. Prescriptions were most common among older people (aged 70–79 and 80 + years), and much less common among younger people (aged 20–29 and 30–39 years). Significant linear declines over time were apparent in all age groups except the 50–59-year group. Linear regression showed statistically significant annual declines in morphine prescriptions per 1000 population for all age groups (except the 50–59-years group) of: 20–29 years, 0.78 (95% CI, 0.73–0.82; P < 0.001); 30–39 years, 2.11 (95% CI, 1.81–2.41; P < 0.001); 40–49 years, 1.21 (95% CI, 0.59–1.83; P = 0.02); 50–59 years (no change; P = 0.44); 60–69 years, 1.99 (95% CI, 1.68–2.31; P < 0.001); 70–79 years, 5.39 (95% CI, 3.96–6.82;
2 Indicators of harms associated with “other opioid”* and heroin use in Australia†

(A) Hospital separations for opioid poisoning

<table>
<thead>
<tr>
<th>Year</th>
<th>Other opioids</th>
<th>Heroin</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999–00</td>
<td>0.00</td>
<td>0.16</td>
</tr>
<tr>
<td>2000–01</td>
<td>0.06</td>
<td>0.14</td>
</tr>
<tr>
<td>2001–02</td>
<td>0.08</td>
<td>0.12</td>
</tr>
<tr>
<td>2002–03</td>
<td>0.10</td>
<td>0.10</td>
</tr>
<tr>
<td>2003–04</td>
<td>0.12</td>
<td>0.08</td>
</tr>
<tr>
<td>2004–05</td>
<td>0.14</td>
<td>0.06</td>
</tr>
<tr>
<td>2005–06</td>
<td>0.16</td>
<td>0.04</td>
</tr>
<tr>
<td>2006–07</td>
<td>0.18</td>
<td>0.02</td>
</tr>
<tr>
<td>2007–08</td>
<td>0.20</td>
<td>0.00</td>
</tr>
</tbody>
</table>

(B) Treatment episodes for problems related to morphine, oxycodone and heroin

<table>
<thead>
<tr>
<th>Year</th>
<th>Morphine</th>
<th>Oxycodone</th>
<th>Heroin</th>
</tr>
</thead>
<tbody>
<tr>
<td>2000–01</td>
<td>0.00</td>
<td>0.16</td>
<td>0.14</td>
</tr>
<tr>
<td>2001–02</td>
<td>0.02</td>
<td>0.14</td>
<td>0.12</td>
</tr>
<tr>
<td>2002–03</td>
<td>0.04</td>
<td>0.12</td>
<td>0.10</td>
</tr>
<tr>
<td>2003–04</td>
<td>0.06</td>
<td>0.10</td>
<td>0.08</td>
</tr>
<tr>
<td>2004–05</td>
<td>0.08</td>
<td>0.08</td>
<td>0.06</td>
</tr>
<tr>
<td>2005–06</td>
<td>0.10</td>
<td>0.06</td>
<td>0.04</td>
</tr>
<tr>
<td>2006–07</td>
<td>0.12</td>
<td>0.04</td>
<td>0.02</td>
</tr>
<tr>
<td>2007–08</td>
<td>0.14</td>
<td>0.02</td>
<td>0.00</td>
</tr>
</tbody>
</table>

*Morphine, oxycodone, and codeine. † Data obtained from the Australian Institute of Health and Welfare's Alcohol and Other Drug Treatment Services National Minimum Dataset and National Hospital Morbidity Database.

3 All opioid-related mortality and oxycodone mortality for 2002–2008‡

<table>
<thead>
<tr>
<th>Parameter</th>
<th>2002</th>
<th>2003</th>
<th>2004</th>
<th>2005</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>All opioid-related deaths§</td>
<td>364</td>
<td>357</td>
<td>357</td>
<td>374</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxycodone deaths</td>
<td>31</td>
<td>46</td>
<td>48</td>
<td>59</td>
<td>61</td>
<td>94</td>
<td>59</td>
</tr>
<tr>
<td>Calculated defined daily doses of oxycodone¶ (millions)</td>
<td>4.26</td>
<td>5.74</td>
<td>7.59</td>
<td>9.20</td>
<td>11.09</td>
<td>13.33</td>
<td>15.6</td>
</tr>
<tr>
<td>Oxycodone deaths per million defined daily doses</td>
<td>7.3</td>
<td>8</td>
<td>6.3</td>
<td>6.4</td>
<td>5.5</td>
<td>7.1</td>
<td>3.8</td>
</tr>
</tbody>
</table>

* Data from Degenhardt and Roxburgh, the National Coronial Information System, and the Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee. † 2001 and 2009 figures have been omitted in the event that these cases are not complete. ‡ Includes oxycodone deaths; changes in data collection render trends beyond 2005 not comparable. ¶ These calculations relate to all oral oxycodone preparations that were dispensed on the Pharmaceutical Benefits Scheme.

P < 0.001; 80+ years, 12.61 (95% CI, 9.12–16.11; P < 0.001). All trends were strongly linear (R² for linear trend, ≥ 0.91, except the 40–49-years age group [R² = 0.73]).

Analysis of prescriptions by dosage strength (data not shown) showed that the 15–30 mg formulations accounted for the largest proportion (34.5%) of all oral morphine prescriptions. This declined slightly but significantly between 2002–03 and 2007–08 (annual decline, 0.25%; 95% CI, 0.17%–0.34%; P < 0.001). The stronger formulations — 50–60 mg and 90 mg and over (predominantly 100 mg tablets) — accounted for relatively smaller proportions of all formulations (21.4% and 19.5%, respectively) in 2007–08. However, the market share of these stronger formulations relative to all morphine prescriptions increased between 2002–03 and 2007–08 (annual increase, 0.26% [95% CI, 0.12%–0.40%; P = 0.02] and 0.48% [95% CI, 0.35%–0.61%; P < 0.001], respectively). Prescriptions for the 60 mg and 100 mg tablets were most common among the 40–49-year age group, and have remained relatively stable (data not shown).

In contrast, oxycodone prescriptions in Australia increased markedly from 35.3 to 89.2 per 1000 population between 2002–03 and 2007–08, representing an increase of about 152%. Significant linear increases over time are apparent across all age groups (Box 1B). Linear regression showed statistically significant (P ≤ 0.001) annual increases per 1000 population for each group: 20–29 years, 1.64 (95% CI, 1.27–2.00); 30–39 years, 4.55 (95% CI, 4.19–4.92); 40–49 years, 8.59 (95% CI, 8.28–8.90); 50–59 years, 11.14 (95% CI, 10.58–11.70); 60–69 years, 19.02 (95% CI, 17.04–21.00); 70–79 years, 33.23 (95% CI, 30.73–35.72); 80+ years, 59.17 (95% CI, 54.66–63.68). All trends were strongly linear (R² for linear trend, ≥ 0.94).

Analysis of prescriptions by dosage strength shows that 5 mg, 10 mg and 20 mg formulations accounted for the largest proportion of all oral oxycodone prescriptions (30.2%, 21.6% and 19.6%, respectively) in 2007–08 (data not shown). The proportion of 10 mg formulations increased significantly from 16.1% in 2002–03 (annual increase, 1.08%; 95% CI, 0.75%–1.41%; P < 0.001). The most potent formulation (80 mg) accounted for the smallest proportion of prescriptions (6.3% in 2007–08), and this has been stable across time. Age analysis shows that prescriptions for 80 mg tablets were highest among the 40–49-years age group, and increased by about 25% in this group over time (data not shown).

Hospital separations

The number of hospital separations for poisoning with “other opioids” (morphine, oxycodone and codeine, but not heroin) was higher in 2007–08 (0.11 per 1000 population) than in 1999–00 (0.05 per 1000 population). Hospital separations almost doubled in 2006–07 (Box 2A).

Outpatient treatment episodes

Treatment episodes for problematic morphine use remained relatively stable during 2002–03 to 2007–08 (0.07 per 1000 population in 2007–08). Episodes for problematic oxycodone use doubled, from 0.01 per 1000 population in 2002–03 to 0.02 per 1000 population in 2007–08 (Box 2B).

Oxycodone-related deaths

There were 465 oxycodone-related deaths identified between 2001 and 2009. Box 3 shows deaths by year from 2002 to 2008, with the largest number occurring in 2007. Deaths adjusted for quantity of oxycodone prescribed each year fluctuated between 3.8 and 8 deaths per million defined daily doses (Box 3). Only 10% of these deaths were due to oxycodone toxicity alone. Multiple drug toxicity was more predominant (82% of deaths), with benzodiazepines and alcohol commonly implicated in these deaths. The remaining 8% were from other causes (eg, pneumonia or cardiac failure), with drug toxicity (including oxycodone toxicity) being a contributory cause (data not shown).

Median age at death related to oxycodone was 42 years (range, 15–86 years), with most deaths occurring among 40–49-year-olds (31%), followed by 30–39-year-olds (27%). A quarter of decedents (124; 27%) were median age at death related to oxycodone was 42 years (range, 15–86 years), with most deaths occurring among 40–49-year-olds (31%), followed by 30–39-year-olds (27%). A quarter of decedents (124; 27%) were
IDUs. In half of the cases of oxycodone-related death (53%), it was recorded that oxycodone had been prescribed to the decedents, and half of the decedents (52%) had a history of a chronic medical condition and/or pain. About a quarter of oxycodone-related deaths (27%) were recorded as suicides (Box 4).

IDUs were significantly more likely than non-IDUs to be male (76% v 46%; OR, 1.7; 95% CI, 1.4–2.1), while non-IDUs were significantly older than IDUs (46.0 years v 37.5; \( t_{351} = 7.3; P < 0.001 \)), and significantly more likely than IDUs to have intentionally taken an overdose (35% v 6%; OR, 6.3; 95% CI, 3.0–13.1). Non-IDUs were also significantly more likely than IDUs to have been prescribed oxycodone at the time of their death (76% v 35%; OR, 4.5; 95% CI, 2.8–7.4) and to have a chronic medical condition (72% v 35%; OR, 3.5; 95% CI, 2.4–5.2).

Discussion

This is the first Australian report to document oxycodone-related mortality at a national level, and it provides important clarification of prescription trends. There is increasing concern in Australia that problems related to oxycodone seen in the United States might be emerging here. Although there are lessons to be learned from the US experience, the prescription, use and diversion of morphine and oxycodone occurs within a different context in Australia. Opioid analgesic deaths, among which oxycodone is prevalent, now outnumber those for heroin and cocaine in the US. It is important to consider these issues in Australia with reference to the local evidence base.

Overall, the rate of morphine prescribing in Australia has declined across most age groups, with prescriptions remaining most common for people aged over 80 years. In contrast, oxycodone prescribing has increased markedly, particularly among older Australians (those aged 60 years and over), who most commonly receive low-dose formulations. Higher dose formulations of both morphine and oxycodone constituted a minority of overall prescriptions, and were most common among 40–49-year-olds.

The recent increase in hospital separations for opioid poisoning in Australia is concerning, but we were unable to ascertain what proportion of this increase is attributable to oxycodone and morphine; or over-the-counter medications containing codeine. Treatment episodes for problematic use of morphine have remained relatively stable, while those for oxycodone have increased. However, numbers of treatment episodes still remain much lower than those for heroin (for which there were 15 571 in 2007–08).

Oxycodone-related deaths have increased in number over the past 7 years, and were most prominent among 40–49-year-olds. Most of these deaths occurred among people who were not IDUs, had a chronic medical condition, and had been prescribed oxycodone. A quarter of decedents were IDUs, and about a third of this group also had a chronic medical condition. Oxycodone-related deaths overall remain lower in number than heroin-related deaths.

Once these deaths are adjusted for the quantity of oxycodone prescribed (per million defined daily doses), the trend shows relatively low mortality. The contribution of prescription morphine formulations to opioid mortality in Australia remains largely unknown.

Our findings have important implications for ongoing monitoring. Oxycodone prescriptions are clearly increasing in Australia, but the increase may be consistent with appropriate treatment of pain among older Australians. Developing a national real-time prescription system, accessible by medical practitioners and pharmacists, including diagnosis information, would provide important context in understanding the extent of prescription and use of pharmaceutical opioids while improving patient care. It may also reduce the potential for non-medical use and diversion of these drugs, which has been found to be linked with increased rates of mortality in North America.

Our findings have implications for treatment and policy responses aimed at minimising non-medical use and diversion of, and harms related to, opioid analgesics. As problems with the use of these drugs increase, making options for treating dependence more available is crucial, as is developing strategies to enhance the engagement of non-IDU populations in these services. There is a continued need for comprehensive training of general practitioners in assessing and prescribing opioids for patients with chronic non-malignant pain, including ongoing monitoring and review of medication, particularly...
given the complexity of these patients’ presentations.7 Opioid prescribing should not be the first-line response to pain management, particularly given that long-term use of opioids may: (i) lower the threshold to pain; and (ii) be ineffective in targeting pain long-term.23

Evidence suggests that there is a large psychological component to the experience of chronic pain,23 and research investigating the efficacy of non-pharmacological interventions for pain management is needed. Given that a minority of oxycodeone-related deaths are occurring among IDUs, messages about the harms associated with these drugs need to reach a broader audience. Greater focus on policy monitoring, and on treatment responses among non-IDU populations, is therefore essential. Finally, given the prevalence of suicide among oxycodeone-related deaths, these risks need to be considered by GPs during their evaluation of patients for prescription of opioid analgesics, and during ongoing patient monitoring.

Our findings lead us to make the following key recommendations:

• A national online prescription system should be developed and training and ongoing support should be provided for health practitioners in prescribing opioid analgesics, to reduce diversion.

• The efficacy of non-pharmacological responses to pain management should be investigated.

• GPs should monitor their patients’ medication use and mental health issues to minimise the risk of intentional overdose among patients with chronic pain.

Our study has certain limitations that must be acknowledged. The NHMD does not differentiate between morphine, oxycodeone or codeine poisonings, and some case reports suggest that the increase in “other opioid” poisonings may be attributable to over-the-counter codeine preparations.24 Systematic recording of the morbidity and mortality associated with codeine preparations would be pertinent, particularly given that these are not regulated in Australia.

Further, the NCIS may yield an underestimate of deaths related to oxycodeone, as implicated drugs may have been miscoded or misspelt. However, data administrators undertake quality assurance work regularly to minimise the impact of errors. We undertook a range of search strategies for this report in an effort to maximise the numbers of records returned.

In conclusion, the available data suggest that prescriptions for oxycodeone are increasing in Australia, but these are predominantly for low-dose formulations, and for older patients. Part of the increase may reflect appropriate prescribing for pain. Oxycodeone-related deaths in Australia do not appear to have reached proportions seen in the US. Access to effective pain relief is an important human right, which should not be overlooked in the debate about policy responses regarding the prescribing of these drugs in Australia.

Acknowledgements: We acknowledge the Australian Institute of Health and Welfare for providing the NHMD and the ADATS-NMDS data, and the state and territory health departments for agreeing to our access to these data. We also acknowledge the Victorian Institute of Forensic Medicine for access to the NCIS. Finally, we acknowledge the Drug Utilisation Sub-Committee Secretariat, Australian Government Department of Health and Ageing for providing the prescription data. Particular thanks to Maxine Robinson and Vanna Mabbott for help and advice in calculating the daily defined doses per million for oxycodeone prescriptions.

Competing interests: Briony Larance has received untied educational grants from Reckitt Benckiser for two studies. Reckitt Benckiser has no knowledge of, or role in, the development or writing of this article.

Received 14 Dec 2010, accepted 29 Jun 2011.


